Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.
The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.
The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform.
PTC Therapeutics, Inc. has collaborations with F.
Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean.
PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 25, 24 | -1.20 Increased by +36.17% | -1.24 Increased by +3.23% |
| Mar 12, 24 | -2.06 Decreased by -8.99% | 0.50 Decreased by -512.00% |
| Oct 26, 23 | -1.76 Decreased by -15.03% | -1.17 Decreased by -50.43% |
| Aug 3, 23 | -2.66 Decreased by -24.88% | -1.71 Decreased by -55.56% |
| Apr 27, 23 | -1.88 Decreased by -5.62% | -1.52 Decreased by -23.68% |
| Feb 21, 23 | -1.89 Increased by +6.90% | -1.59 Decreased by -18.87% |
| Oct 27, 22 | -1.53 Increased by +19.05% | -1.24 Decreased by -23.39% |
| Aug 4, 22 | -2.13 Decreased by -26.79% | -1.33 Decreased by -60.15% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 196.58 M Decreased by -9.46% | -132.97 M Decreased by -21.64% | Decreased by -67.64% Decreased by -34.36% |
| Jun 30, 23 | 213.81 M Increased by +29.17% | -198.88 M Decreased by -30.77% | Decreased by -93.02% Decreased by -1.24% |
| Mar 31, 23 | 220.38 M Increased by +48.17% | -138.96 M Decreased by -9.65% | Decreased by -63.05% Increased by +26.00% |
| Dec 31, 22 | 167.41 M Increased by +1.32% | -170.89 M Decreased by -19.28% | Decreased by -102.08% Decreased by -17.73% |
| Sep 30, 22 | 217.13 M Increased by +56.50% | -109.31 M Increased by +18.19% | Decreased by -50.35% Increased by +47.73% |
| Jun 30, 22 | 165.53 M Increased by +41.87% | -152.09 M Decreased by -28.48% | Decreased by -91.88% Increased by +9.43% |
| Mar 31, 22 | 148.74 M Increased by +26.11% | -126.73 M Increased by +1.49% | Decreased by -85.20% Increased by +21.88% |
| Dec 31, 21 | 165.23 M Increased by +39.01% | -143.26 M Decreased by -92.68% | Decreased by -86.71% Decreased by -38.61% |